When Dr. Philip Toleikis joined Sernova in 2009, the company's technology appeared as more of a concept than anything else. But, he saw the potential for something groundbreaking: A cure for type 1 diabetes (T1D). "I just thought it was an … [Read More...] about How Sernova seeks to treat insulin-dependent diabetes with its Cell Pouch System
Main Content
Sponsored Content
Discovering Antigen-specific Monoclonal Antibodies using Single B Cell Screening
Introduction Since the approval of Orthoclone OKT3 in 1986, more than 100 monoclonal antibodies (mAbs) have been approved by the Food and Drug Administration (FDA) to treat a variety of diseases … [Read More...] about Discovering Antigen-specific Monoclonal Antibodies using Single B Cell Screening
Featured Posts
How Sernova seeks to treat insulin-dependent diabetes with its Cell Pouch System
When Dr. Philip Toleikis joined Sernova in 2009, the company's technology appeared as more of a concept than anything else. But, he saw the potential for something groundbreaking: A cure for type 1 diabetes (T1D). "I just thought it was an … [Read More...] about How Sernova seeks to treat insulin-dependent diabetes with its Cell Pouch System
TriSalus releases positive data for its catheter-based drug delivery tech
TriSalus Life Sciences today announced positive clinical results for its Pressure-Enabled Regional Immuno-Oncology technology. The company, currently in the process of going public through a SPAC merger, filed a presentation for investors. It … [Read More...] about TriSalus releases positive data for its catheter-based drug delivery tech
FDA says Insulet Omnipod Dash batteries recall is Class I
The FDA has posted a notice that an Insulet recall related to Omnipod Dash batteries is Class I, its most serious level. Insulet recently issued a voluntary global safety notice to warn about battery problems. The Omnipod Dash is Insulet’s … [Read More...] about FDA says Insulet Omnipod Dash batteries recall is Class I
Abbott FreeStyle LibreLink app now pairs with Novo Nordisk insulin pens in UK
Novo Nordisk (NYSE:NVO) announced that users of the Abbott (NYSE:ABT) FreeStyle LibreLink app can connect to its smart insulin pens. People living with diabetes in the United Kingdom can connect the app to the Novo Nordisk smart, connected pens. … [Read More...] about Abbott FreeStyle LibreLink app now pairs with Novo Nordisk insulin pens in UK
Tandem stock ticks up after Wells Fargo upgrade
Tandem Diabetes Care (Nasdaq:TNDM) shares ticked up today after Wells Fargo declared it "Equal Weight," an improvement from "Underweight." Shares of TNDM rose 8.3% at $42.81 apiece in midday trading today. MedTech 100 Index — which includes stocks … [Read More...] about Tandem stock ticks up after Wells Fargo upgrade
Pear Therapeutics posts mixed bag Q3, cuts 22% of workforce
Pear Therapeutics (Nasdaq:PEAR) stock is down today — a day after it reported mixed third-quarter results. The Boston-based prescription digital therapeutic (PDT) developer also announced a large set of layoffs yesterday evening. The new layoffs … [Read More...] about Pear Therapeutics posts mixed bag Q3, cuts 22% of workforce
Insulet issues device correction on Omnipod 5 controller due to charging issue
Insulet (Nasdaq:PODD) announced a medical device correction for its Omnipod 5 automated insulin delivery system. Acton, Massachusetts-based Insulet's correction relates to an issue with the Omnipod 5 controller's charging port and cable. The … [Read More...] about Insulet issues device correction on Omnipod 5 controller due to charging issue
Medtronic launches 7-day infusion set for insulin pumps in U.S.
Medtronic (NYSE:MDT) announced today that it launched its Medtronic Extended Infusion set for seven-day wear with insulin delivery. The Medtronic Extended Infusion Set represents the first and only infusion set labeled for wearing of up to seven … [Read More...] about Medtronic launches 7-day infusion set for insulin pumps in U.S.
Oramed inks deal to commercialize oral insulin in the Republic of Korea
Oramed Pharmaceuticals (Nasdaq:ORMP) announced today that it entered into a distribution agreement for its oral insulin candidate in the Republic of Korea. The New York-based developer of oral drug delivery platforms entered into an exclusive … [Read More...] about Oramed inks deal to commercialize oral insulin in the Republic of Korea
Study supports Tandem t:slim X2 insulin pump for type 2 diabetes
Tandem Diabetes Care (Nasdaq:TNDM) announced that a study of adults with type 2 diabetes supported its automated insulin delivery system. The study evaluated adults with type 2 diabetes using the t:slim X2 insulin pump with Control-IQ technology. … [Read More...] about Study supports Tandem t:slim X2 insulin pump for type 2 diabetes
In case you missed it
- Eli Lilly to start rollout of Tempo personalized diabetes management platform
- Senseonics down on tightened guidance — but it hits milestone on 365-day implantable CGM
- Ascensia Diabetes integrates its Eversense CGM with Apple Health
- Insulet warns of battery issues with some Omnipod Dash PDM devices
- Insulet stock rises on Street-beating Q3, raised sales guidance
- Sernova to enroll second cohort in trial of Cell Pouch System for type 1 diabetes
- Ascensia, Senseonics partner with Nurse Practitioner Group on CGM insertion options
- Tandem stock dives on Q3 misses, reduced guidance
- Fractyl Health forms task force to understand root causes of type 2 diabetes
- Ascensia launches online diabetes management, analytics platform in U.S.
- Health Canada licenses Medtronic next-gen MiniMed 780G insulin pump
- Here’s what diabetes tech companies are doing for National Diabetes Awareness Month
- Enable Injections to add hundreds of jobs in Ohio
- Dexcom stock rises on Q3 results following G7 international rollout
- Abbott FreeStyle Libre named ‘best medical technology’ in last 50 years by Galien Foundation
Clinical Trials
How Sernova seeks to treat insulin-dependent diabetes with its Cell Pouch System
When Dr. Philip Toleikis joined Sernova in 2009, the company’s technology appeared as more of a concept than anything else. But, he saw the potential for something groundbreaking: A cure for type 1 diabetes (T1D). “I just thought it was an incredible idea,” said Toleikis, who serves as Sernova’s president and CEO. “We spent a […]
TriSalus releases positive data for its catheter-based drug delivery tech
TriSalus Life Sciences today announced positive clinical results for its Pressure-Enabled Regional Immuno-Oncology technology. The company, currently in the process of going public through a SPAC merger, filed a presentation for investors. It features information regarding its ongoing PERIO 01 and PERIO 02 clinical studies. The studies evaluate the TriNav pressure-enabled drug delivery technology for […]
Study supports Tandem t:slim X2 insulin pump for type 2 diabetes
Tandem Diabetes Care (Nasdaq:TNDM) announced that a study of adults with type 2 diabetes supported its automated insulin delivery system. The study evaluated adults with type 2 diabetes using the t:slim X2 insulin pump with Control-IQ technology. Patients achieved improvement in all clinical endpoints with the technology, which currently does not hold approval for type […]
Sernova to enroll second cohort in trial of Cell Pouch System for type 1 diabetes
Sernova announced today that it received approval for a protocol amendment in the trial of its Cell Pouch System for treating type 1 diabetes. London, Ontario-based Sernova designed its proprietary Cell Pouch System as an implantable and scalable medical device. It forms a natural environment in the body for the long-term survival and function of […]
BioCorRx completes enrollment in trial of naltrexone implant for treating opioid use disorder
BioCorRx (OTC:BICX) announced today that it enrolled the last subject in the Phase I clinical trial of its BICX104 implant. Anaheim, California-based BioCorRx designed BICX104 for the treatment of opioud use disorder (OUD). Its BioCorRx Pharmaceuticals company developed the implantable, biodegradable naltrexone pellet. “We are pleased to have reached this significant milestone,” said Brady Granier, […]
